

1208 teriparatide

• **Blood dyscrasias:** Monitor CBC, platelets 6 mo before use and periodically, monitor for infection, monitor INR

Black Box Warning: Pregnancy: do not start treatment until pregnancy is ruled out; this product should not be used during pregnancy or for 2 yr after stopping the drug; those wishing to become pregnant must discontinue the product and undergo an accelerated elimination procedure with verification of teriflunomide plasma level <0.02 mg/L; do not use in breastfeeding

Evaluate:

• Therapeutic response: decreased symptoms of MS

Teach patient/family:

- That blurred vision can occur
- That hair may be lost, that a wig or hairpiece may be used
- Not to change dosing or stop taking without advice of prescriber
- To report skin changes, rashes immediately
- To avoid live virus vaccines; that updated vaccines should be done before use
- To report signs, symptoms of infection
- Teach patient to take as directed, provide "Medication Guide"
- Teach patient to notify provider of nausea, vomiting, loss of appetite, dark urine, yellow eyes or skin

Black Box Warning: To notify prescriber if pregnancy is planned or suspected; do not use in pregnancy or breastfeeding

teriparatide (Rx)

(tah-ree-par'ah-tide)

Forteo

Func. class.: Parathyroid hormone (rDNA)

Chem. class.: Teriparatide

ACTION: Contains human recombinant parathyroid hormone to stimulate new bone growth

USES: Postmenopausal women with osteoporosis, men with primary or hypogonadal osteoporosis who are at high risk for fracture, glucocorticoid-induced osteoporosis

Unlabeled uses: Hypoparathyroidism

CONTRAINDICATIONS: Hypersensitivity, increased baseline risk for osteosarcoma (Paget's disease, open epiphyses; previous bone radiation), bone metastases, history of skeletal malignancies, other metabolic bone diseases, preexisting hypercalcemia

Precautions: Pregnancy, breastfeeding, children, urolithiasis, hypotension, use >2 yr, cardiac disease

Black Box Warning: Secondary malignancy (osteogenic sarcoma)

DOSAGE AND ROUTES

• **Adult:** SUBCUT 20 mcg/day up to 2 yr

Available forms: Prefilled pen delivery device (delivers 20 mcg/day)

Administer:

SUBCUT route

- Give by SUBCUT using disposable pen only; inject in thigh or abdomen; lightly pinch fold of skin; insert needle; release skin; inject at 90-degree angle over 5 sec; rotate inj sites
- Have patient sit or lie down; orthostatic hypotension may occur
- Protect from freezing, light; refrigerate pen
- Store refrigerated; do not freeze; may be used for 28 days after first inj

SIDE EFFECTS

CNS: Dizziness, headache, insomnia, depression, vertigo

CV: Hypertension, angina, syncope

GI: Nausea, diarrhea, dyspepsia, vomiting, constipation

INTEG: Rash, sweating

MISC: Pain, asthenia, hyperuricemia

MS: Arthralgia, leg cramps, back/leg pain, weakness, **osteosarcoma (rare)**

RESP: Rhinitis, cough, pharyngitis, pneumonia, dyspnea